Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
18F-FluorThanatrace PET/CT in Breast Cancer
NCT03083288Phase 1Active, not recruiting
- Sponsor
- Abramson Cancer Center
- Start
- Feb 2017
- Primary completion
- Jul 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of [18F]FluorThanatrace in breast cancer, sponsored by Abramson Cancer Center. Primary endpoint: Number of adverse events at 2 years. Started Feb 2017; status: active, not recruiting.
02
Drugs
[18F]FluorThanatrace
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03083288.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03083288.